Previous investigations report an association between in situ ENO1 overexpression and a worse clinical outcome in a variety of tumors, such as pancreatic adenocarcinoma 25, hepatocellular carcinoma 28, 42, glioma 14, breast cancer 15, and head and neck cancer 17. Here, ENO1 is linked to glioma.